|Bid||3.1200 x 1000|
|Ask||3.2400 x 3000|
|Day's Range||2.9150 - 3.0900|
|52 Week Range||0.8800 - 4.2500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.58|
NEW YORK, May 01, 2020 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice.
Neon Therapeutics, Inc. (NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority (DHA) for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01. Neon’s initial Phase 1 clinical trial of NEO-PTC-01 will be in patients with metastatic melanoma who are not responsive to checkpoint inhibitors. NEO-PTC-01 is a personal neoantigen-targeted T cell therapy candidate derived from patients’ peripheral blood mononuclear cells (PBMCs) and consisting of multiple T cell populations targeting the most therapeutically relevant neoantigens from each patient’s tumor.
WILMINGTON, Del., April 27, 2020 -- Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of.